wire - news in brief


Category


Years
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

Last News


Results 201 - 250 of 362.

Physics/Materials Science - Chemistry
07.07.2017
X-ray Lasers Show Mechanisms behind Superconductors and Magnetic Switching
X-ray Lasers Show Mechanisms behind Superconductors and Magnetic Switching
Research experience from California's X-ray free-electron laser benefits SwissFEL It's the camera that allows researchers to make extremely rapid processes visible: the X-ray free-electron laser. Currently, however, only three sites worldwide—in the US, Japan and South Korea—have facilities capable of carrying out such measurements.
Administration/Government - Careers/Employment
06.07.2017
Ten years of the European Research Council: positive record from Swiss perspective
Bern, 06.07.2017 - An event was held in Geneva on 6 July to mark the tenth anniversary of the European Research Council (ERC).
Medicine/Pharmacology
06.07.2017
Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis
Label update includes 52 week data from CLEAR study demonstrating long-term superiority of Cosentyx versus Stelara in psoriasis ,   Update also includes use of Cosentyx in moderate-to-severe scalp ps
Agronomy/Food Science - Medicine/Pharmacology
05.07.2017
Naturalness as a success factor
Naturalness as a success factor
"Naturalness" is a construct - but according to a new study from the ETH Consumer Behavior group, a product's success on the food market is primarily defined by whether or not consumers perceive it as natural. The increasingly artificial and virtual nature of everyday life has now achieved broad acceptance, and the benefits that technological development bring to everyone cannot be denied.
Computer Science/Telecom - Mathematics
04.07.2017
On fast track at ETH
On fast track at ETH
At the age of 29, Professor of Computer Science Mohsen Ghaffari is one of the youngest professors at ETH Zurich.
Life Sciences
04.07.2017
Praying Mantises Hunt Down Birds Worldwide
Praying Mantises Hunt Down Birds Worldwide
A study by zoologists from Switzerland and the US shows: praying mantises all over the globe also include birds in their diet. The Wilson Journal of Ornithology has just published the results. Praying mantises are carnivorous insects with powerful raptorial front legs that usually depend on arthropods such as insects or spiders as their primary prey.
Chemistry - Careers/Employment
03.07.2017
Meeting Nobel Laureates
Meeting Nobel Laureates
ETH Zurich's Thomas Gianetti meets up with the world's most promising Young Scientists at the Lindau Nobel Laureate Meeting.
Environment/Sustainable Development
01.07.2017
«We have to talk about what the future
«We have to talk about what the future
In May 2016, Patrick Wäger took over the helm at Empa's Technology and Society lab. Closing material cycles and performing life cycle and technology assessments are just some of the topics that now come under his dominion.
Computer Science/Telecom - Microtechnics/Electroengineering
29.06.2017
Building with robots and 3D printers
Building with robots and 3D printers
At the Empa and Eawag NEST building in Dübendorf, eight ETH Zurich professors are collaborating with business partners to build the three-storey DFAB HOUSE.
Chemistry - Physics/Materials Science
29.06.2017
Fuel and chemicals from plant waste
Fuel and chemicals from plant waste
From the inexhaustible raw material lignin, which as a constituent of many plants accumulates in great quantities, fuels and other important substances could in theory be extracted for industry - so far, though, it can't be done efficiently enough. Researchers at the Paul Scherrer Institute PSI and ETH Zurich have now found a method for identifying heretofore unseen intermediate products of the catalytic reactions used for this conversion.
Medicine/Pharmacology - Life Sciences
29.06.2017
Novartis receives EU approval for first-line use of Zykadia in ALK-positive advanced non-small cell lung cancer (NSCLC)
In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival (PFS) compared to SOC chemotherapy with maintenance   Zykadia benefit was also seen in patients
Mathematics - Physics/Materials Science
29.06.2017
Light switches from a spray can
Light switches from a spray can
Researchers are on the lookout for rapid, reliable and affordable switches for the opto-electronics of the future.
Life Sciences - Medicine/Pharmacology
29.06.2017
Designed Proteins to Treat Muscular Dystrophy
Designed Proteins to Treat Muscular Dystrophy
The cell scaffolding holds muscle fibers together and protects them from damage. Individuals who suffer from muscular dystrophy often lack essential components in this cell scaffold. As a result, their muscles lack strength and become progressively weaker. The research team of Prof. Markus Rüegg at the Biozentrum, University of Basel, has now designed two proteins that stabilize the cell scaffolding link it to the muscle fiber and thereby restore muscle structure and function.
Medicine/Pharmacology - Life Sciences
28.06.2017
The gene behind follicular lymphoma
The gene behind follicular lymphoma
EPFL scientists have discovered an important gene whose loss lies behind follicular lymphoma, an incurable cancer. Follicular lymphoma is an incurable cancer that affects over 200,000 people worldwide every year. A form of non-Hodgkin lymphoma, follicular lymphoma develops when the body starts making abnormal B-cells, which are white blood cells that in normal conditions fight infections.
Medicine/Pharmacology - Life Sciences
27.06.2017
Sandoz receives approval in Europe for Erelzi (biosimilar etanercept) to treat multiple inflammatory diseases
European Commission approves Sandoz Erelzi to treat immunological diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis Approval of Erelzi provides more treatment options for heal
Computer Science/Telecom - Business/Economics
27.06.2017
More security in cyberspace
More security in cyberspace
At yesterday's Cyber Risks Summit at ETH Zurich, international experts discussed and presented the latest scientific and technological approaches for effectively protecting society from the dangers of cyberspace.
Medicine/Pharmacology - Administration/Government
27.06.2017
Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF)
Fewer pills, more flexibility in dosing: Roche's new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) New immediate-release tablet formulation of
Physics/Materials Science - Environment/Sustainable Development
26.06.2017
Microplastics from the washing machine
Microplastics from the washing machine
Even before the UN Ocean Conference in early June, we already knew about the disastrous ways in which plastic affects the world's oceans. Billions of pieces of plastic are floating in the oceans. Their effects are also sufficiently well-known: marine animals swallow them or get tangled up in them, which causes them to die in agony.
Physics/Materials Science - Astronomy
26.06.2017
A gravity researcher in search of weightlessness
A gravity researcher in search of weightlessness
Lavinia Heisenberg is a theoretical physicist. She is reluctant to accept that General Relativity can be used to describe the universe only on the assumption of exotic materials and energy sources.
Civil Engineering/Traffic Engineering
26.06.2017
Medicine/Pharmacology - Life Sciences
26.06.2017
Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors
Roche's emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Emicizumab showed substantial and clinically meaningful reduction in bleeds across two pivotal studies Data from HAVEN 1 in adults and adolescents and interim data from HAVEN 2 in children to be presented at the 26th International Society on Thrombosis and Haemostasis (ISTH) Meeting Roche today announced positive data from the p
Medicine/Pharmacology - Life Sciences
23.06.2017
NEJM publishes full analysis of Rydapt (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
Significant overall survival benefit observed for FLT3+ AML patients consistent across FLT3 mutation subgroups, including ITD and TKD Detailed data show Rydapt plus standard chemotherapy improved eve
Medicine/Pharmacology - Life Sciences
23.06.2017
Novartis Kisqali (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
Novartis Kisqali (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor CHMP opinio
Medicine/Pharmacology - Life Sciences
23.06.2017
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data   Data evaluating 63 patients demonstrate relapse-free survival and probability of survival in a majority of patients at six months   Advances in CTL019 and ELIANA result from global CAR-T cell therapy collaboration with the University of Pennsylvania   CTL019 is manufactured us
Medicine/Pharmacology - Chemistry
23.06.2017
Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna
New 96-week data support durability and safety of Treatment-free Remission (TFR) in Ph+ CML-CP patients who stop taking Tasigna [1,2] More than 90% of Ph+ CML-CP patients in ENESTfreedom and ENESTop who stopped Tasigna and were in TFR at 48 weeks remained in TFR at 96 weeks [1,2] 48-week data from same trials recently added to Tasigna SmPC following EC approval; discussions with other regulatory authorities are underway worldwide - Novartis toda
Medicine/Pharmacology
23.06.2017
Four out of Five People in Switzerland Use Contraception
Which contraceptives are used in Switzerland and by whom? The first Swiss report on contraception describes contraceptive trends, frequency and methods in Switzerland from 1992 to 2012.
Medicine/Pharmacology - Life Sciences
23.06.2017
Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers
Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers First in class BCL2-specific oral inhibitor represents a potential new way of treating different blood cancers Efficacy and tolerability confirmed in high-risk patients with relapsed or refractory chronic lymphocytic leukaemia, including those with 17p chromosomal de
Medicine/Pharmacology - Physics/Materials Science
23.06.2017
Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma
Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma Longer follow-up showed sustained benefit in progression-free survival of Gazyva/Gazyvaro-based treatment over MabThera/Rituxan-based treatment regardless of chemotherapy regimens People with follicular lymphoma who received Gazyva/Gazyvaro-based treatment reported improvement in health-related qualit
Medicine/Pharmacology - Life Sciences
23.06.2017
FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes, compared to 1.5 hour
Medicine/Pharmacology - Life Sciences
23.06.2017
Novartis combination targeted therapy Tafinlar + Mekinist receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
Novartis combination targeted therapy Tafinlar + Mekinist receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC) Approval provides first targeted treatment in the U
Computer Science/Telecom - Event
22.06.2017
Medicine/Pharmacology
22.06.2017
ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces cardiovascular risk in people with a prior heart attack and inflammatory atherosclerosis   Despite current treatments about 40% of heart attack survivors remain at increased risk of  recurrent heart attack, stroke or cardiovascular death because of hi
Medicine/Pharmacology - Life Sciences
21.06.2017
Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance
AMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance   Filing is supported by a comprehensive clinical program o
Astronomy - Media
20.06.2017
Switzerland in pole position in ESA’s new mission
Media releases, information for representatives of the media Media Relations (E) PLATO, the largest European exoplanet research mission, was adopted on 20 June 2017 by the European Space Agency at the ESA Scientific Programs Committee meeting. The Universities of Bern and Geneva are heavily involved in this mission, which should enable astronomers to discover and characterize planets the size of the Earth and the "super 'Earths" that orbit around solar type stars in their habitable zone.
Medicine/Pharmacology
20.06.2017
Transportation Noise Increases Risk for Cardiovascular Diseases and Diabetes
Transportation Noise Increases Risk for Cardiovascular Diseases and Diabetes
Transportation noise increases risk for cardiovascular diseases and diabetes. This is shown by the first results of the SiRENE study under the lead of Swiss TPH, which was presented today in the framework of the ICBEN Congress (International Commission on Biological Effects of Noise) in Zurich. How transportation noise affects the health of people remains in many aspects unexplained.
Computer Science/Telecom - Mathematics
20.06.2017
‘We have to seize this opportunity'
‘We have to seize this opportunity’
Die Digitalisierung verändert grundlegend immer mehr Lebensbereiche. Für ETH-Präsident Lino Guzzella ist klar: Dieser Wandel ist für die Schweiz eine grosse Chance, denn sie hat ideale Voraussetzungen, eine leistungsfähige Digitalindustrie aufzubauen.
Medicine/Pharmacology
20.06.2017
Almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden
Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden Urgent need to improve management of chronic urticaria (CU) - a disease that causes itchy, persistent hives and swelling which last more than 6 weeks or recur over months or years - highlighted by study of over 3,700 patients , 42% of CU patients studied are not receiving any treatment for their debilitatin
Medicine/Pharmacology
20.06.2017
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
RTH258 achieved the primary efficacy endpoint of non-inferiority to aflibercept in mean change in BCVA from baseline to week 48 , in two head-to-head pivotal Phase III studies ,   57% and 52% of patients receiving RTH258 6 mg in the respective trials were maintained exclusively on a q12w interval immediately following the loading phase and continuing through week 48 ,   In both studies overall ocular and non-ocular adverse event rates for RTH258
History/Archeology - Earth Sciences
20.06.2017
A Wooden Toe: Swiss Egyptologists Study 3000-Year-Old Prosthesis
A Wooden Toe: Swiss Egyptologists Study 3000-Year-Old Prosthesis
It is likely to be one of the oldest prosthetic devices in human history: Together with other experts, Egyptologists from the University of Basel have reexamined an artificial wooden big toe. The find is almost 3000 years old and was discovered in a female burial from the necropolis of Sheikh ´Abd el-Qurna close to Luxor.
Computer Science/Telecom
19.06.2017
Piz Daint is a world leader
Piz Daint is a world leader
After an extensive hardware upgrade at the end of last year, the CSCS supercomputer Piz Daint is now the most powerful mainframe computer outside Asia.
Computer Science/Telecom - Microtechnics/Electroengineering
19.06.2017
Medicine/Pharmacology - Life Sciences
19.06.2017
Sandoz receives approval in Europe for Rixathonâ? (biosimilar rituximab) to treat blood cancers and immunological diseases
European Commission approves Sandoz Rixathon â? to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare systems to reallocate resources to other healthcare priorities.
Environment/Sustainable Development
19.06.2017
Lessons from whale population collapse could help future species at risk
The research, carried out by scientists at the University of Zurich and University of Tasmania, used detailed records collected during the commercial whaling of the 20 th century and collated by the International Whaling Committee (IWC) - to look at the effects of overharvesting on whale populations, and used this historic data to help develop methods which can be applied to species of current conservation concern.
Medicine/Pharmacology
17.06.2017
Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease
Large-scale European patient survey found that 94% of severe allergic asthma patients were unable to fully control their disease â? These new data underscore the disconnect between self-perceived control and clinical reality; a potentially limiting factor in patients seeking support to better control their condition â? Helping patients recognize the possibilities of living a life with properly controlled asthma is central to a major new global p
Sport Sciences - Environment/Sustainable Development
16.06.2017
A video game demonstrates how energy choices affect our carbon footpr
‘Mission Possible' combines scientific rigor and good fun to help us understand the carbon impact of our personal energy choices.
Physics/Materials Science - Medicine/Pharmacology
16.06.2017
Radon Increases Risk for Malignant Skin Cancer
A new study by the Swiss Tropical and Public Health Institute (Swiss TPH) about residential radon exposure in Switzerland shows that the radioactive gas radon increases the risk for developing malignant skin cancer. It is undisputed that radon is a risk factor for developing lung cancer. New research by the Swiss Tropical and Public Health Institute (Swiss TPH) in the context of the Swiss National Cohort study now shows that the naturally occurring radioactive gas radon within one's home also increases the risk to develop malignant skin cancer (malignant melanoma).
Careers/Employment
16.06.2017
EPFL spin-offs flourish in a finely tuned ecosystem
EPFL spin-offs flourish in a finely tuned ecosystem
A recent report by EPFL's Vice Presidency for Innovation (VPI) shows just how effective the school's startup ecosystem is by looking at standard benchmarks such as the number of jobs created, funds raised, and the buyout rate for campus startups.

 
 
Jobs listed on